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Background: Burkitt lymphoma is an aggressive B-cell lymphoma presenting in three clinical forms: endemic,
sporadic and immunodeficiency-associated. More than 90% of endemic Burkitt lymphoma carry latent Epstein-Barr
virus, whereas only 20% of sporadic Burkitt lymphoma are associated with Epstein-Barr infection. Although the
Epstein-Barr virus is highly related with the endemic form, how and whether the virus participates in its pathogenesis
remains to be fully elucidated. In particular, the virus may impair cellular gene expression by its own encoded
microRNAs.
Methods: Using microRNA profiling we compared Epstein-Barr-positive and Epstein-Barr-negative Burkitt lymphoma
cases for both cellular and viral microRNAs. The array results were validated by qRT-PCR, and potential targets of viral
microRNAs were then searched by bioinformatic predictions, and classified in functional categories, according to the
Gene Ontology. Our findings were validated by in vitro functional studies and by immunohistochemistry on a larger
series of cases.
Results: We showed that a few cellular microRNAs are differentially expressed between Epstein-Barr-positive and
Epstein-Barr-negative Burkitt lymphoma cases, and identified a subset of viral microRNAs expressed in Epstein-Barr-
positive Burkitt lymphomas. Of these, we characterized the effects of viral BART6-3p on regulation of cellular genes. In
particular, we analyzed the IL-6 receptor genes (IL-6Rα and IL-6ST), PTEN and WT1 expression for their possible relevance
to Burkitt lymphoma. By means of immunohistochemistry, we observed a down-regulation of the IL-6 receptor and
PTEN specifically in Epstein-Barr-positive Burkitt lymphoma cases, which may result in the impairment of key cellular
pathways and may contribute to malignant transformation. On the contrary, no differences were observed between
Epstein-Barr-positive and Epstein-Barr-negative Burkitt lymphoma cases for WT1 expression.
Conclusions: Our preliminary results point at an active role for the Epstein-Barr virus in Burkitt lymphomagenesis and
suggest new possible mechanisms used by the virus in determining dysregulation of the host cell physiology.
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Burkitt lymphoma (BL) has represented a key model for
understanding multi-stage tumorigenesis [1]. It was the
first tumor for which the association with an infectious
agent was demonstrated [2]. The discovery in the 1960s
of its association with the Epstein-Barr virus (EBV) be-
came a foundation stone of human tumor virology [3].
Later, in the 1980s the identification of c-MYC/Ig fusion
at the site of t(8;14) translocation has set a path that has
opened the molecular basis of oncogenic changes in
many other tumor context [4,5]. BL is now listed in the
World Health Organization (WHO) classification of tu-
mors of hematopoietic and lymphoid tissue as an aggres-
sive B-cell non-Hodgkin’s lymphoma with three subsets,
endemic (eBL), sporadic (sBL) and immunodeficiency-
associated (ID-BL), which mainly differ for geographic
distribution, clinical presentation and association with
EBV [6].
More recently, focus has been restored on BL in a way
that again highlights its potential in revealing new in-
sights. Whole genome analysis elucidated the existence
of common gene-coding mutations in BL [7].
Gene expression profile (GEP) has demonstrated that
BL has a unique molecular profile, distinct from those of
other B-cell non-Hodgkin lymphomas (B-NHLs) and, es-
pecially, from that of diffuse large B-cell lymphoma
(DLBCL) [8,9]. In addition, we have described differences
in terms of gene and microRNA expression among sBL
and eBL [10,11]. eBL cases show an enrichment of genes
involved in the B-cell receptor-signalling pathway, suggest-
ing a direct role of chronic antigenic stimulation in Burkitt
lymphomagenesis [10]. Most eBL are associated with EBV
and occur in areas in which malaria is endemic, but there
is still no satisfactory explanation of how and whether the
virus participates in BL pathogenesis. EBV may impact on
host cell homeostasis in various ways by interfering with
cellular microRNAs (miRNAs) expression and by encod-
ing its own genes and miRNAs; in fact we have recently
demonstrated that EBNA1 is able to induce the expression
of cellular miRNAs in BL [12]. The EBV genome encodes
for 45 mature microRNAs from 25 precursors, which are
mapped in 2 regions of the genome: BHRF1 (Bam HI
fragment H rightward open reading frame I) and BART
(Bam HI-A region rightward transcript) [13]. The BART
region encodes the cluster 1 and cluster 2 EBV-miRNAs,
whereas the BHRF1 region contains only 3 miRNAs [14].
EBV-encoded miRNAs are differentially expressed among
the different latency programs, being the latency III re-
stricted to BHRF1 miRNA expression and the latency I
and II to BART miRNA expression [15]. However, to date,
little information is still available about the expression
of EBV-encoded miRNAs in primary tumours, and their
possible contribution in dysregulating host cell gene ex-
pression [16-20].With the aim to assess the contribution of EBV-
encoded miRNAs in Burkitt lymphomagenesis, we pro-
filed a number of EBV-positive and EBV-negative BL
cases for cellular and viral miRNA expression. Then we
validated our findings by in vitro functional studies and
by immunohistochemistry on samples from a larger,
well-characterized cohort of cases, with the attempt to
shed light on new possible mechanisms used by the
virus to contribute to malignant transformation and to
favor the design of more specific treatments for EBV-
associated malignancies. Our preliminary results point at
an active role for the Epstein-Barr virus in Burkitt lym-
phomagenesis and suggest new possible mechanisms




The study was approved by the Ethics Committee of
Nairobi Hospital, CNIO Madrid, Spain and Siena Uni-
versity Hospital, Italy. Study participants or their legal
guardians provided written informed consent.
Cases selection
For this study 71 BL cases, collected at the Department
of Pathology, Nairobi Hospital, Kenya, CNIO biobank,
Madrid, Spain and at the Department of Medical Bio-
technologies, University of Siena, Italy, have been used.
Cases were reviewed by expert pathologists and diagno-
ses were confirmed according to the WHO [6]. Among
the 40 eBL cases, 38 were EBV positive, whereas only 3
out the 31 sBL cases were EBV positive.
For miRNA profiling, 18 BL cases (six EBV-positive and
twelve EBV-negative) have been used. Immunohistochem-
ical studies were performed on representative sections of
35 EBV-positive and 18 EBV-negative formalin-fixed and
paraffin embedded (FFPE) BL samples.
EBER-in-situ hybridization (ISH) and EBV latency analysis
The presence of EBV was assessed by in situ hybridization
for EBERs using Epstein-Barr Virus (EBER) PNA/Fluores-
cein (Dako, Milan-Italy), a mixture of PNA probes com-
plementary to the two nuclear EBER RNAs encoded by
EBV, in conjunction with Dako PNA ISH Detection Kit,
according to manufacturer’s instructions. A control
slide, prepared from a paraffin-embedded tissue block
containing metastatic nasopharyngeal carcinoma in a
lymph node, accompanied each hybridization run.
The expression of EBV-encoded genes (EBNA1, LMP1,
EBNA2, Zebra), which characterize the different latency
programs, has been investigated by qRT-PCR using Taq-
man probes, as previously described [21]. In addition, the
expression of the relative proteins were checked by
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EBNA1 at gene and protein level.
MicroRNA extraction
Total RNA was extracted from FFPE sections of primary
tumors and reactive lymph nodes using the PPPE miRNA
Easy kit (Qiagen, CA), and from fresh tissues of eighteen
cases of BL (six EBV-positive BLs and twelve EBV-
negative BLs) was extracted using the miRNA Easy Kit
(Qiagen, CA), according to the manufacturer’s instruc-
tions. The amount and quality of RNA were evaluated by
measuring the optic density (OD) at 260 nm, the 260/230
and the 260/280 ratios using a Nanodrop spectrophotom-
eter (ND-1000, Nanodrop, Thermo Scientific, Celbio-
Italy). The cases were subjected to the Agilent® Human
microRNA microarray technology (Agilent, Cernusco sul
Naviglio-Italy) following manufacturer instructions.
MicroRNA microarray expression profiling
Total RNA was extracted from fresh tissues of eighteen
cases of BL (six EBV-positive BLs and twelve EBV-
negative BLs) using TRIZOL reagent (Invitrogen, CA).
For miRNA detection, 100 ng of total RNA were
hybridized on a one color Agilent Human miRNA Micro-
array (Agilent Technologies, Inc., Santa Clara, CA) follow-
ing manufacturer instructions [22]. Scanning was carried
out using the Microarray Scanner System (Agilent). Micro-
array images were processed using feature extraction soft-
ware (Agilent technologies). Background subtraction and
quantile normalization has been applied by using a script
developed in collaboration with CNIO bioinformatics unit.
To compare EBV-positive versus EBV-negative samples, a
T-test that includes correction for multiple testing was per-
formed using the web site: http://pomelo2.bioinfo.cnio.es/
[23]. miRNAs showing FDR (False Discovery Rate; q-value)
below the value of 0.05 were considered differentially
expressed between the two groups. A heatmap of miRNAs,
whose FDR was below 0.05, has been constructed using
the web site: www.gepas.org. The microarray data has been
deposited at the National Center for Biotechnology Infor-
mation Gene Expression Omnibus database (accession
number: GSE52916).
Computational analysis and gene ontology
Target genes of the differentially expressed miRNAs iso-
lated by profiling were identified by computational ana-
lysis, using web-available resources (Mirnaviewer, PicTar,
Tarbase [24], miRBase) [25] and miRGate. miRGate is a
tool developed in collaboration with bioinformatics unit at
CNIO (Madrid). Target genes common to more than one
prediction algorithm were considered. Functional studies
were then performed on selected genes possibly of interest
for BL. Genes were classified in functional categories ac-
cording to the Gene Ontology [26].Real-time quantitative reverse transcription PCR (qRT-PCR)
Validation of both cellular (hsa-miR181d, hsa-miR609,
hsa-miR574, hsa-miR197, hsa-miR142-5p, hsa-miR7,
hsa-miR501-5p, hsa-miR510) and viral miRNAs, and the
expression level of a selection of possible target genes,
was obtained by RT-qPCR, using the specific Taqman
microRNA Assays for cellular and viral miRNAs (Ap-
plied Biosystems, Germany), following manufacturer’s
instructions. For target gene validation, reverse tran-
scription was performed using the QuantiTect Reverse
Transcription Kit (Qiagen, CA) and qPCR was made
using the QuantiTect SYBR Green PCR Kit (Qiagen,
CA), according to the manufacturer’s instructions. qRT-
PCR was performed using a Rotorgene machine (Qiagen,
CA). Exported result files were then loaded into Data
Assist Software v2.0 (Applied Biosystems) for statistical
analysis of differences in gene and miRNA expression.
Normalization was made on RNU43, GAPDH and 18S
rRNA which were stably expressed among the samples,
and relative quantification was performed using the
ΔΔCt method [27]. Statistical analysis was performed
using the T-test [23].
Immunohistochemistry
Representative sections (4-μm thick) were placed on
positively charged glass slides (ProbeOn Plus; Fisher Sci-
entific, Pittsburgh, PA, USA). The staining was carried
out on Bond III automated immunostainer (Leica Micro-
system, Bannockburn, IL, USA) and diaminobenzidine
(DAB, Leica Microsystem, Bannockburn, IL, USA) was
used as chromogen. A large panel of antibodies (See the
list of stains) was applied and reactive lymph nodes were
used as control. Expression level of both chains of
Interleukin-6 (IL-6) receptor (p80 and gp130), PTEN
and WT-1 protein was assessed using immunohisto-
chemistry in 53 BL primary tumors (35 EBV-positive
and 18 EBV-negative). A detailed list of the antibodies
and working condition is reported in Table 1. Immuno-
reactivity was assessed by two blinded investigators and
the expression levels were classified semiquantitatively
combining the proportion and intensity of positively
stained cells [28]. The percentage of positive-staining
cells was scored as follows: 1 (<5% positive cells), 2 (5-
50% positive cell), and 3 (>50% positive cells). Staining
intensity was scored as follows: 1 (weak or not detect-
able staining), 2 (moderate staining) and 3 (strong stain-
ing). The sum of the staining intensity score and the
percentage score was used to define the protein expres-
sion level, calculated as HSCORE [28]: 1, low expression;
2, moderate expression; 3, high expression. Differences
in protein expression between EBV-positive and EBV-
negative BL cases were analyzed using the Chi-square
test. The level of statistical significance was established
at p < 0.05.
Table 1 List of antibodies and their respective
concentrations
Primary antibody Dilution Company
CD20 (IHC) RTU Novocastra- Leyca system, Milan (Italy)
CD10 (IHC) RTU Novocastra- Leyca system, Milan (Italy)
Bcl-6 (IHC) RTU Novocastra- Leyca system, Milan (Italy)
Bcl-2 (IHC) RTU Novocastra- Leyca system, Milan (Italy)
CD38 (IHC) RTU Novocastra- Leyca system, Milan (Italy)
CD44 (IHC) RTU Novocastra- Leyca system, Milan (Italy)
IgM (IHC) 1:100 Dako, Milan (Italy)
Ki-67 (IHC) 1:100 Novocastra- Leyca system, Milan (Italy)
p80 (IHC) 1:10 Abcam, Cambridge (UK)
gp130 (IHC) 1:50 Abcam, Cambridge (UK)
PTEN (IHC) 1:50 Dako, Milan (Italy)
WT-1 (IHC) RTU Novocastra- Leyca system, Milan (Italy)
PTEN (WB) 1:500 Dako, Milan (Italy)
gp130 (WB) 1:500 Abcam, Cambridge (UK)
p80 (WB) 1:500 Abcam, Cambridge (UK)
phospho IκB-α (WB) 1:1000 Cell Signaling, Monza, Italy
Phosphor Akt (WB) 1:500 Cell Signaling, Monza, Italy
EBNA1 (WB) 1:100 Santa Cruz Biotechnology, Santa Cruz,
CA, USA
Actin (WB) 1:1000 Abcam, Cambridge, UK.
RTU: ready to use.
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BL-derived cell lines were used for in vitro studies. Briefly,
Ramos (EBV-negative), Raji (EBV-positive) were obtained
from the American Type Culture Collection (ATCC). The
Akata cell line (EBV-positive) and its defective counterpart
Akata 2A8 (which is an EBV-negative variant of the Akata
cell line) were kindly provided by Prof. Trivedi (University
La Sapienza, Rome, Italy). Ramos and Raji cells were cul-
tured in RPMI 1640 medium supplemented with 10% Fetal
Bovine Serum (FBS), 2 mM glutamine, 100U/ml penicillin
and 100 μg/ml streptomycin (all from Lonza, Swiss). Akata
cells were cultured in the same medium as Ramos cell line,
supplemented with 1 mM sodium pyruvate and 100 nM
MEM non-essential amino acids (both from Gibco-Life
Technologies, Monza-Italy). For inhibition of the endogen-
ous EBV-Bart6-3p, cells were grown in growth medium, as
previously described before transfections. Proliferation rate
was measured by Tripan blue staining.
Cell transfection
Based on the highest level of expression of BART6-3p,
in vitro studies using mimic and inhibitor sequences of
BART6-3p were performed in Akata cells. Briefly, tran-
sient transfections of the Akata cell line were performed
using an Amaxa nucleofector apparatus (Amaxa, Cologne-
Germany), program G23 and transfection solution Vaccording to the manufacturer’s instructions. 5×106 cells
were transfected with 100 nM of BART6-3p inhibitor
(Custom synthesized by Dharmacon- Thermo Scientific,
Germany), 10 nM of negative control of miRNA inhibitor
(I-300145-01; Dharmacon-Thermo Scientific, Germany) or
the transfection solution as a mock. Transfection efficiency
was assessed using transfecting 2 μg of pmaxGFP and
detecting both fluorescence and cell viability by flow cy-
tometry. Cells were harvested 24 hours after transfection
for RNA extraction and qRT-PCR and 48 hours post-
transfection for protein extraction and western blotting.
Western blotting
Western botting was performed as previously described
[17]. Briefly, cells pellets were lysed on ice for in EBC
buffer (50 nM Tris–HCl pH 8.0, 130 mM NaCl, 1% Tri-
ton X-100, 0.1% SDS) supplemented with protease in-
hibitor cocktail (Sigma, Milan-Italy). Cell lysates were
separated by 10% SDS-PAGE gel followed by transfer to
Hybond ECL nitrocellulose membrane (GE Healthcare,
Milan, Italy). Secondary antibodies conjugated with HRP
were used at a dilution of 1:5000 and the reaction was
revealed using the ECL Western Blotting Kit (Promega,
Milan-Italy) according to the manufacturer’s instructions.
Antidody dilutions are reported in Table 1. Secondary
antibodies conjugated with HRP were used at a dilution of
1:5000 and the reaction was revealed using the ECL West-
ern Blotting Kit (W1001, Promega, Milan-Italy) according
to the manufacturer’s instructions.
Detection of apoptosis
Apoptosis was analyzed by flow cytometric analysis of
cells stained with FITC-conjugated Annexin V and
50 μg/ml PI using Annexin V apoptosis Detection kit
FITC (eBioscence). Samples were analyzed in a FACScan
flow cytometer (Becton Dickinson, San Jose, CA) using
CellQuest software. Doublets were excluded and 20.000
events were acquired for each sample.
Results
Epstein Barr-positive Burkitt lymphoma and Epstein
Barr-negative Burkitt lymphoma differ for both cellular
and viral miRNAs
With the aim of identifying the EBV-encoded miRNAs
expressed in BL primary tumors, we performed a micro-
RNA profiling comparing EBV-positive versus EBV-negative
BL cases, using a platform containing both cellular and
viral miRNAs. The profiling identified 8 out of 470 cellular
miRNAs, which were differentially expressed between
EBV-positive and EBV-negative BLs (FDR < 0.05). In
particular, 3 of these were up-regulated (hsa-miR-7,
hsa-miR-501-5p, hsa-miR-510) and 5 miRNAs were
down-regulated (hsa-miR-181d, hsa-miR-609, hsa-miR-
574, hsa-miR-197, hsa-miR142-5b) in EBV-positive BL
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NAs were found to be expressed in EBV-positive BL
cases, all of which were from the BART coding region,
including both BART cluster 1 and BART cluster 2 (Fig-
ure 1a). None of BHRF coding region miRNAs was found
to be expressed in EBV-positive BL cases, confirming that
BHRF miRNAs are not expressed in latency I. ValidationFigure 1 microRNA profiling of EBV-positive vs. EBV-negative BL case
versus EBV-negative BL cases. 12 EBV-negative and 6 EBV-positive BL cases
the Agilent® microRNA expression microarray technology. While each colum
expressed in two groups or viral miRNAs expressed in EBV-positive cases. W
and -negative BLs (FDR < 0.05). Indeed 13 out of 46 EBV miRNAs were foun
of the array results on the cellular miRNAs differentially expressed between
three different qRT-PCR experiments. Error bars represent standard deviatioand confirmation of the array results on cellular miRNAs
was performed by qRT-PCR (Figure 1b).
Key cellular pathways may be affected by dysregulated
cellular and viral miRNAs
Potential target genes of cellular and viral dysregulated
miRNAs were identified by prediction algorithms, ands. (a) Heatmap of miRNA differential expression in EBV-positive BL
were compared in terms of viral and human miRNA expression using
n represents a BL case, rows represent human miRNAs differentially
e recognized 8 out of 470 cellular miRNA deregulated in EBV-positive
d to be expressed in EBV-positive BL cases. (b) Validation by RT-qPCR
EBV-positive and EBV-negative BL cases. The graph is representative of
n between duplicates.
Table 3 Target genes of BART6-3p and their respective
functions
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cording to the Gene Ontology [26]. This analysis revealed
their involvement in cell cycle, proliferation, signal trans-
duction, apoptosis and differentiation (Table 2).
Based on these predictions, we focused on BART6-3p, as
it is supposed to regulate the expression of cellular genes
involved in relevant cellular pathways, including tumor
suppressors and signal transducers, whose imbalance may
crucially contribute to malignant transformation (Table 3).
In particular, BART6-3p is predicted to regulate the ex-
pression of PTEN, WT1 and of both chains of IL-6 recep-
tor (p80 and gp130), which are involved in key cellular
functions such as proliferation, apoptosis, and immune
surveillance. The expression of these genes was therefore
analyzed by immunohistochemistry in additional 35 EBV-
positive and 18 EBV-negative BL primary tumors. Both
chains of IL-6 receptor and PTEN expression significantly
differed between EBV-positive and EBV-negative cases,
being both proteins strongly down-regulated in the for-
mer. p80 showed a cytoplasmic pattern with a membrane
reinforcement whereas gp130 displayed a membrane and
somewhat cytoplasmic expression. PTEN exhibited a
strong nuclear positivity. Higher p80, gp130 and PTEN
expression was observed in EBV-negative BL cases in com-
parison with EBV-positive BL cases (p < 0.001). The cor-
relation between p80 and gp130, and PTEN expression in
all BL samples is given in Tables 4, 5 and 6. In the EBV-
positive cases showing IL-6 receptor and PTEN expression,
the positivity was mild. Macrophages served as internal
positive control for all the antibodies (Figure 2). On the
contrary, no differences were appreciated between EBV-
positive and EBV-negative BL cases for WT-1, that resulted
not expressed in all of 53 cases (data not shown).
BART6-3p modulates the expression of IL-6 receptor and
PTEN in vitro
To confirm the possible regulation by BART6-3p on
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SOD2performed a series of in vitro experiments using BL-
derived cell lines, expressing the same latency program
as BL primary tumors. First of all, we analyzed several
EBV-positive BL-derived cell lines for the expression
of BART6-3p, to select an appropriate cell model for
functional studies.
Our results indicated the Akata cell line as the most
suitable cell model, because of the high endogenous
levels of BART6-3p (Figure 3a).
We then monitored whether the expression of the se-
lected target genes could be modulated upon inhibition
of the endogenous BART6-3p, in the Akata cell line.
Therefore, to confirm that the differential expression of
these genes was specifically dependent on BART6-3p,
we ectopically modulated the expression of the endogen-
ous BART6-3p in the Akata cells, by transiently trans-
fecting a synthetic BART6-3p inhibitor.
The expression level of both subunits of the IL-6 re-
ceptor and PTEN was then checked by qRT-PCR 24 hrs
after transfection; inhibition of BART6-3p was also













Total (n.) 35 18 53
BL: Burkitt lymphoma; n.: number of cases.
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in the up-regulation of both chains of the IL-6 receptor
and PTEN, both at the mRNA (Figure 3b) and protein
levels (Figure 3c).
We then evaluated whether the up-regulation of these
genes, consequent to BART6-3p inhibition, may affect
their respective downstream pathways. Following binding
of IL-6 with its receptor, a downstream signaling is trans-
duced through the activation of NF-κB. This requires
cleavage of NF-κB, which occurs through phosphorylation
and consequent degradation of its inhibitor IκB-α. To de-
termine whether IL-6 receptor up-regulation resulted in
NF-κB activation, we measured the levels of phosphoryl-
ation of its inhibitor IκB-α.
The up-regulation of the IL-6 receptor, resulting from
BART6-3p inhibition, leads in turn to the activation of
NF-κB signaling, as demonstrated by increased phos-
phorylation of IκB-α. On the other hand, PTEN nega-
tively regulates the activation of Akt, which occurs
through phosphorylation of the Akt protein. Activation
of PTEN, following BART6-3p inhibition, results in a de-
crease of the Akt phosphorylation and consequent Akt
activity (Figure 3c).
BART6-3p influences cell proliferation and cell death
We investigated whether this viral microRNA could have
an effect in terms of cell viability. The effects of BART6-
3p on cell proliferation were monitored upon inhibition
of the endogenous viral microRNA by an antagomir.
Silencing BART6-3p resulted in a decrease of the prolif-













Total (n.) 35 18 53
BL: Burkitt lymphoma; n.: number of cases.that cells transfected with BART-6-3p inhibitor had a
higher mortality rate, when compared to negative control,
measured by Tripan blue staining (data not shown). To
specifically detect whether cell death could be due to in-
duction of apoptosis, we performed Annexin V staining
on cells transfected with the inhibitor of BART6-3p. Our
results demonstrated that inhibition of BART6-3p resulted
in an increase of apoptosis (Figure 4b).
Discussion
Since its discovery as the first human tumor virus, EBV
has been implicated in the development of a wide range
of B-cell lymphoproliferative disorders, the first being
BL [29-31]. However, the exact mechanism by which
EBV promotes oncogenesis is still matter of discussion
[32-34]. EBV may contribute to transformation through its
encoded genes and/or miRNAs [35,36]. There is increasing
evidence of a complex interplay between viruses and the
cellular miRNA machinery, with viruses that encode their
own miRNAs and viruses that actually employ cellular
miRNAs as co-factors for replication [20]. EBV-encoded
miRNAs may compete with cellular miRNAs and target
cellular genes, thus dysregulating cellular pathways [35].
Therefore, the EBV-encoded miRNAs dramatically in-
crease the complexity of potentially biologically active mol-
ecules produced by EBV during latent infection and could
also have consequences on the pathogenicity of the infec-
tion [37,38].
To address a better knowledge of the role of EBV in
BL, in this study we have compared EBV-positive versus
EBV-negative BL cases by miRNA expression profile.
Interestingly, the platform we used included both cellu-
lar and viral miRNAs, to highlight the contribution of
EBV-encoded miRNAs in regulating host cellular gene
and miRNA expression.
Our results identified few cellular miRNAs differentially
expressed between EBV-positive and EBV-negative BL, be-
ing in line with recent studies, although different platforms
and different techniques may be responsible for subtle dif-
ferences [10,18,19]. Among the differentially expressed cel-
lular miRNAs, hsa-miR-197 was found to be specifically
down-regulated in EBV-positive BL tumors. This finding
may be of interest, as this miRNA is predicted to regulate
BCL6, which is a key regulator of germinal center exit and
differentiation towards plasma cells. Previous studies from
our group report that B-cell differentiation is impaired in
EBV-positive BL due to the combinatory expression of
hsa-miR-127 and EBNA1 [11,18]. Therefore, hsa-miR197
down-regulation may add complexity to the regulatory
network of B-cell differentiation in BL.
We focused on EBV-encoded miRNAs, as their pos-
sible relevance for Burkitt lymphomagenesis has been
poorly explored. Interestingly, we observed that all of
the viral miRNAs expressed in EBV-positive BL cases
Figure 2 Immunohistochemistry of BART6-3p target genes. The expression level of p80, gp130 and PTEN was evaluated in EBV-positive (right)
and EBV-negative (left) BL cases. p80 was strongly expressed in the cytoplasm (upper panel), gp130 showed membrane and cytoplasmic positivity
(middle panel), PTEN was found in the nucleus (lower panel). Macrophages were used as internal positive controls. p80, gp130 and PTEN were
found to be meaningfully down-regulated in EBV positive BL cases (right panel, upper, middle and lower images, respectively).
(400x magnification).
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cluster 2, whereas no miRNAs from the BHRF regions
were expressed. The absence of BHRF1 miRNAs from
EBV-associated tumors is consistent with the latency I
program expressed by BL, confirming previous reports
on EBV-encoded miRNA expression in EBV-associated
tumors [14]. Among all the BART-derived miRNAs, in
this paper we focused on BART-6-3p, as it is predicted
to target several cellular genes involved in cell cycle, cell
proliferation, apoptosis, signal transduction, differenti-
ation. Dysregulation of these pathways may crucially
affect key cellular homeostasis. In particular, we evalu-
ated the expression of PTEN, WT1 and IL-6 receptor
(p80, gp130) genes, as they act as tumor suppressors and
signal transducers. A marked down-regulation of PTEN
and IL-6 receptor in EBV-positive cases was demon-
strated. To confirm that BART6-3p regulates theexpression of these genes, functional in vitro studies
were carried out revealing that modulation of BART6-
3p expression is inversely related to that of PTEN and
IL-6 receptor subunits. These results were also con-
firmed by analyzing PTEN and IL-6 receptor down-
stream genes.
PTEN functions as a tumor suppressor by negatively
regulating the Akt/PI3K signaling pathway, which is
overactive if PTEN is faulty or deficient, thus reducing
apoptosis and allowing proliferation by induction of
mTOR [39]. Impairment of PTEN may result in a growth
advantage of infected cells, which may eventually contrib-
ute to malignant transformation [40]. In line with this ob-
servation, we found that re-expression of PTEN following
BART6-3p inhibition results in increase of apoptosis, and
in a reduction of the proliferation rate, which is in line
with PTEN negative regulatory function.
Figure 3 BART6-3p-regulated pathways in BL-derived cell lines. (a) The expression of BART6-3p was evaluated in two EBV-negative
BL-derived cell lines (Akata 2A8 and Ramos) and two EBV-positive BL-derived cell lines (Akata and Raji), to select that expressing BART6-3p at the
highest level. The Akata cell line shows higher expression level of BART6-3p. (b): qRT-PCR of BART6-3p target genes following BART6-3p inhibition.
A BART6-3p antagomir was transfected in Akata cells and the expression level of p80, gp130 and PTEN was evaluated 24 hrs post-transfection.
Cells transfected with BART6-3p inhibitor showed a marked up-regulation of p80, gp130 and PTEN, in respect with cells transfected with the
negative control (NC), confirming regulation of these genes by BART6-3p. As a control, down-regulation of the endogenous BART6-3p was
observed following transfection with the antagomir. The graph is representative of three different qRT-PCR experiments. Error bars represent
standard deviation between duplicates. (c): Inhibition of BART6-3p by its antagomir results in the activation of the downstream pathways of the
IL-6 receptor (p80 and gp130) and PTEN. The expression of p80, gp130 and PTEN was evaluated at the protein level by WB. In addition, two
downstream signaling pathways were also evaluated following BART6-3p inhibition, the activation of NF-κB, which occurs through IκBα
phosphorylation, and the decrease of the phosphorylated form of Akt, which acts downstream from PTEN. Protein levels were evaluated 48 hours
post-transfection by Western blotting. The bands were then analyzed by the Image J software and relative expression levels were normalized to
those of β-actin. Activation of NF-κB is consequent to IκB-α phosphorylation; PTEN activity results in the negative regulation of Akt, documented
by a lower phosphorylation level. EBNA1 expression was measured as a control for EBV-positivity. The figure is representative of three
different experiments.
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http://www.infectagentscancer.com/content/9/1/12The IL-6 receptor is a heterodimeric receptor, com-
posed by the subunit alpha (p80), which is specific for
IL-6 binding, and the beta chain (gp130), which is the
common transducer of different cytokines belonging to
the IL-6 family [41]. The IL-6 receptor regulates key cellu-
lar processes as cell proliferation, cell survival, and re-
sponse to host pathogens following the binding of the
dimerized receptor with its specific cytokine (IFN-α, IL-12,IL-27) [41,42]. Interestingly, a recent study has shown that
gp130 is down-regulated in EBV-positive nasopharyngeal
carcinoma primary tumors and determines the lack of acti-
vation of the Jak2/Stat pathway following IL-27 release,
resulting in an impairment of NK cell function and im-
mune surveillance [43]. Here we give evidence for the first
time of the down-regulation of the IL-6 receptor also in
EBV-positive BL primary tumors and derived cell lines.
Figure 4 Effects of BART6-3p on cell viability. (a) The effects of BART6-3p on cell proliferation and cell death were monitored following its
inhibition by a synthetic antagomir, by Tripan blue exclusion assay. Proliferation curves show that inhibition of BART6-3p results in a decreased
proliferation rate, whereas Tripan blue staining revealed an increased in the dead cell fraction (data not shown). (b) To detect whether cell death
could be dependent on apoptosis, an Annexin V staining was performed 24 hrs after inhibitor transfection. Our results indicate an increase of the
apoptotic fraction of cells transfected with BART6-3p inhibitor, in respect with its negative control (NC). The figure is representative of three
different experiments.
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http://www.infectagentscancer.com/content/9/1/12Our findings suggest that this may be due to BART6-3p
through either direct and indirect mechanisms, providing
room for additional functional effects of EBV in evading
the immune response and in contributing to the tumori-
genesis [44-46].
Collectively, our data confirmed that different patho-
genetic mechanisms may exist in EBV-positive and EBV-
negative BL tumors, and that EBV may have a driving
role in Burkitt lymphomagenesis. This may be achieved
through dysregulation of key cellular pathways by viral-
encoded miRNAs. In particular, EBV-BART-6-3p may
play an important role in the pathogenesis of BL, as it
may affect the function of important signal transducers
as NF-κB and Akt/PI3K [47]. In addition, it may inter-
fere with innate and adaptive immune response, contrib-
uting to immune evasion of infected BL cells, and may
impact on cell proliferation, cell growth and apoptosis
by down-regulating PTEN, thus removing the inhibitory
brake on cell proliferation.Conclusions
Despite the encouraging results on viral miRNAs, future
experiments are needed. Nevertheless, our study may
help to clarify the complex regulatory network between
host and pathogen, and may serve as a paradigm for all
the virus-related neoplasms in which pathogenic mecha-
nisms remain still poor understood.Abbreviations
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